zovegalisib

Zovegalisib (formerly RLY-2608) is Relay Therapeutics' mutant-selective PI3Kα inhibitor, now in the Phase 3 ReDiscover-2 trial (NCT06982521) for PIK3CA-mutant HR+/HER2-negative metastatic breast cancer after CDK4/6 inhibitor progression [1][2][9]. The headline from ASCO 2025: median progression-free survival of 10.3 months and a 39% objective response rate in CDK4/6-pretreated patients dosed with zovegalisib plus fulvestrant (doublet, 600mg BID fasted) [1]. Updated data at ESMO TAT March 2026 - at the actual Phase 3 dose of 400mg BID fed - showed 11.1-month mPFS and a 43% confirmed ORR (52% in second-line-only patients) [11]. FDA granted Breakthrough Therapy Designation on February 3, 2026, for zovegalisib plus fulvestrant in CDK4/6-pretreated PIK3CA-mutant HR+/HER2- advanced breast cancer [12]. The commercial pitch is simple: bind only the mutated form of PI3Kα, leave the normal version alone, and avoid the hyperglycemia and rash that capped uptake of Novartis's alpelisib (Piqray). Relay is chasing Roche's inavolisib (Itovebi), approved October 2024 for the same biomarker subgroup in endocrine-resistant patients (CDK4/6-naive in the metastatic setting) [3].

Zovegalisib is a novel small molecule with no approvals anywhere. ReDiscover-2 initiated in mid-2025 per Relay's SEC disclosures [2], with NCT06982521 confirmed via ClinicalTrials.gov [9]. FDA granted Breakthrough Therapy Designation on February 3, 2026 for zovegalisib plus fulvestrant in CDK4/6-pretreated PIK3CA-mutant HR+/HER2- advanced breast cancer [12] - matching inavolisib's regulatory footing through key readout [3][4]. No fast track or orphan designations are reported for the breast cancer program. A separate Phase 1/2 trial, Relnspire, evaluates zovegalisib in PIK3CA-driven vascular anomalies (PIK3CA-related overgrowth spectrum, or PROS - rare congenital disorders where the same activating mutations cause tissue overgrowth rather than tumors) [5]; Relnspire is still early and Relay has not yet released efficacy readouts that allow external evaluation as a near-term catalyst. The PROS indication is a smaller market but could deliver a faster approval given orphan-disease pathways and the absence of approved targeted therapy in that population. Realistic timing for the ReDiscover-2 primary PFS analysis is 2027-2028, depending on event accrual. Recent 8-Ks from Relay (May 2025, June 2025, August 2025, November 2025, February 2026 BTD, April 2026 atirmociclib triplet data) are the place to watch for enrollment, financing, and partnership disclosures [6][7][12][13].

PIK3CA encodes PI3Kα, a protein inside cells that acts like a relay switch for growth signals: when a growth factor docks at the cell surface, PI3Kα flips on and tells the cell to grow and survive. Hotspot mutations (H1047R, E542K, E545K) jam this switch in the on position, driving uncontrolled division. About 40% of HR+/HER2-negative breast cancers carry one of these mutations, making it the most common targetable lesion in the disease [8]. Validation is solid. Alpelisib (Piqray, Novartis) showed in SOLAR-1 that hitting PI3Kα improves PFS in PIK3CA-mutant patients (11.0 vs 5.7 months with fulvestrant) [8]. The problem was off-target effects on wild-type PI3Kα in normal tissue: insulin signaling runs through the same enzyme, so blocking it broadly causes hyperglycemia in roughly 60% of patients, plus rash and diarrhea severe enough to drive discontinuations near 25%. Zovegalisib was designed on Relay's Dynamo computational platform to bind the mutant form preferentially, exploiting subtle shape differences between mutant and wild-type PI3Kα. Phase 1/2 ReDiscover data suggest meaningfully lower hyperglycemia and rash rates than alpelisib at therapeutic exposures [1][11]. Inavolisib takes a different selectivity tactic - it degrades mutant PI3Kα rather than just blocking it [3]. Same biological problem, two distinct selectivity strategies, both improving on alpelisib's blunt approach.

ReDiscover-2 (NCT06982521) is a Phase 3 randomized trial in PIK3CA-mutant HR+/HER2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after a CDK4/6 inhibitor [2][9][13]. Critically, this is a doublet vs. doublet design: the investigational arm is zovegalisib (400mg BID fed) plus fulvestrant; the active comparator is capivasertib (an AKT inhibitor, AstraZeneca's Truqap) plus fulvestrant. Primary endpoint is PFS by blinded independent central review. Two design points matter. First, the comparator choice - capivasertib + fulvestrant, an FDA-approved active regimen in this setting - is a higher bar than placebo + fulvestrant. A win here is more commercially meaningful than a win over endocrine therapy alone. Second, with inavolisib now approved for endocrine-resistant patients earlier in the treatment journey, the post-CDK4/6 population enrolling in ReDiscover-2 will increasingly arrive having seen a PI3Kα-targeting agent, potentially carrying resistance mutations (PTEN loss, second-site PIK3CA mutations) the Phase 1/2 cohort did not face. The Phase 1/2 anchor at ASCO 2025 - 10.3-month mPFS, 39% ORR (600mg BID fasted, CDK4/6-pretreated) - was updated at ESMO TAT March 2026 at the actual Phase 3 dose (400mg BID fed): 11.1-month mPFS, 43% confirmed ORR among 35 patients with measurable disease, 52% ORR in second-line-only patients [1][11]. The slight improvement at the Phase 3 dose is reassuring. The benchmark zovegalisib will be measured against in payer conversations is inavolisib's INAVO120 mPFS of 15.0 months (vs 7.3 months for palbociclib + fulvestrant + placebo) and 34.0-month OS [4][14] - though INAVO120 enrolled an earlier, CDK4/6-naive population, so cross-trial comparison is hazardous. A separate Phase 3 plan was outlined in April 2026 for the zovegalisib + atirmociclib (Pfizer's CDK4-selective inhibitor) + fulvestrant triplet in frontline metastatic breast cancer, supported by early-phase data; this is a distinct program from ReDiscover-2 [13].

Our model estimates a 22% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: inavolisib's earlier-line approval is the dominant external threat [3]. As inavolisib usage expands in endocrine-resistant patients, the post-CDK4/6 population enrolling in ReDiscover-2 will increasingly be PI3Kα-experienced, with resistance mutations zovegalisib may not overcome. The capivasertib + fulvestrant active comparator is also a higher bar than the placebo + endocrine therapy controls used in some earlier PI3Kα trials. Safety risk: mutant selectivity is the entire commercial thesis. If hyperglycemia or rash rates in Phase 3 approach alpelisib's (60% any-grade hyperglycemia, ~25% discontinuation in SOLAR-1), the differentiation collapses [8]. Dose modification and discontinuation rates in the Phase 3 safety population are the numbers to watch. ESMO TAT March 2026 data at the Phase 3 dose described the regimen as 'generally well tolerated' but discontinuation rates against capivasertib in a randomized setting are the test [11]. Execution risk: Relay is clinical-stage with no approved drugs. As of Q1 2026, cash, equivalents, and investments were $642.1M, with runway disclosed into 2029 [15]. That is comfortable for the ReDiscover-2 readout but does not cover commercial launch on its own - a partnership or follow-on financing remains likely before approval. Phase 3 oncology execution (global enrollment, central radiology review, regulatory navigation across FDA and EMA) is expensive and unforgiving for a first-time sponsor. Commercial risk: even with approval, payers may require head-to-head data versus inavolisib or sequencing evidence. Roche has a ~18-24 month head start and an entrenched salesforce in breast oncology. Pricing power depends on whether the safety profile genuinely supports longer dosing duration or broader patient eligibility than alpelisib or inavolisib.

Worth watching. The Phase 1/2 data are credible at the Phase 3 dose, the biology is validated by two approved precedents, the FDA Breakthrough Therapy Designation derisks the regulatory path, and the safety differentiation thesis is testable in a defined timeframe. This is not a binary moonshot. The signal that matters most: ReDiscover-2 interim PFS data, plausibly 2027-2028. Earlier signals to track: (1) Relnspire Phase 1/2 data in PIK3CA-driven overgrowth syndromes - a positive readout in PROS could deliver Relay's first approval ahead of the breast cancer program, though no efficacy data has been published yet to allow external evaluation; (2) the zovegalisib + atirmociclib + fulvestrant frontline triplet program announced April 2026, which opens a second shot at the larger first-line market [13]; (3) quarterly 8-K filings disclosing enrollment milestones, partnership announcements, and any updated FDA interactions [6][7][12]. Relay Therapeutics (RLAY) trades as a story stock driven almost entirely by zovegalisib milestones. The frame is inavolisib (Roche's Itovebi) [3] - and to a lesser extent capivasertib as the active Phase 3 comparator. Two well-differentiated agents can coexist if zovegalisib's safety profile is real, and the PIK3CA-mutant breast cancer market is large enough to support that outcome (the CDK4/6 class shows palbociclib, ribociclib, and abemaciclib all selling at scale despite mechanistic overlap). Check back at Relay's next quarterly earnings, then again at ASCO/SABCS 2026 abstracts to track Phase 3 progress. Drug-quality and biology bars are met; the questions are sponsor execution and whether the addressable post-CDK4/6 population still exists by readout.